Patrick Morris

Artificial Intelligence, Digital & Growth Assets - Not Buy, Sell, Tax and/or Investment Advice.

[Equity investor @equitydd]

Stocks with High Earnings Growth - Keep them on your watchlist 📝

$MU $SKHY $TLS $LITE $FLYW $AVGO $NVDA $CLS $CRDO $CIEN $AMD $TER $SITM $PLTR $ALAB

[Patrick Morris @patrickmorris]

@Laracordels9 @bennyjohnson I hope so. Speaking the truth certainly helps.

[Patrick Morris @patrickmorris]

@Laracordels9 @bennyjohnson Amazing that people still don't see this....

[Lara cordell @Laracordels9]

@bennyjohnson Oh, bullshit! He knew that he wasn’t going to be installed again. It was part of the powers that be (deep state) plan, and he was in on it. By the way, your votes don’t count. Presidents are installed.

[Lin @Speculator_io]

Cybersecurity continues to be one of the leading themes in the market right now.

$CRWD CrowdStrike +12.14%
$OKTA Okta +10.81%
$RPD Rapid7 +8.81%
$TENB Tenable +8.80%
$SAIL Sailpoint +8.49%
$S SentinelOne +7.39%
$ZS Zscaler +7.24%
$PANW Palo Alto +6.84%
$VRNS Varonis + 6.19%
$RBRK Rubrik +4.98%
$NET Cloudflare +4.53%

[Equity investor @equitydd]

$QTTB up 90% today after positive results from its early-stage trial of bempikibart in patients with severe alopecia areata.

[Dan Tapiero @DTAPCAP]

Not calling a low but starting to look very healthy. Maybe need some more time passage. Would be nice to see a few months of base building. Excellent how bad sentiment is. Markets usually do what the majority least expect. Weak surface analysis another great signal.

[Venu @Venu_7_]

IBD Top 15 – Week of July 13

$MU $ALAB $LQDA $CRDO $TVTX $DAVE $PTRN $AMD $CRS $TGTX $ASTH $GH $HNGE $OSCR $LRCX

Study the leaders every single week.

You don't need to own them all.

You just need to understand why institutions do.

[Jordi Visser @jvisserlabs]

The surprise of he AI mid-cycle slowdown is ending.

The last several weeks were a positioning reset, not the end of the structural bull market. Leverage was flushed, semis became deeply oversold, and the narrative turned bearish just as the underlying demand story kept strengthening.

In this week’s video, I cover:

• Why exponential token demand is colliding with linear supply
• Why memory, bandwidth, power and compute remain scarce
• Why the token index is being misunderstood
• How consumer agents could create the next step-function in usage
• Why Scott Bessent told you Bitcoin, stablecoins and agentic commerce are becoming part of the same AI macro story
• What the technical reset means for the next leg higher

The correction changed positioning. It did not change the trajectory.

Watch here: https://t.co/0lrdMKEasd

[Patrick Morris @patrickmorris]

What decides it: hyperscaler capex guidance, the 10-year yield, biotech M&A pace, and distribution days on the Nasdaq. Avg S&P name is already down 21% from its high this year. Manage the stock, not the story.
Not investment advice.

[Patrick Morris @patrickmorris]

$NDX H2 2026 setup for growth stocks: inflation at 4.2%, no Fed cuts coming, earnings still carrying the bull market — but leadership is narrow. Four rotation paths look most probable from here. What each one means, and what would break it 🧵

[Patrick Morris @patrickmorris]

4/ The rotation nobody wants: energy, materials, and staples leading while tech and discretionary lag is a late-cycle signature. If sticky inflation forces rates higher, growth broadly underperforms — and the right move is less exposure, not a different growth stock. Respect this path.

[Patrick Morris @patrickmorris]

3/ The next AI bottleneck isn't chips — it's electricity. Grid capacity, power generation, and data center construction have turned "value" industrials into growth stocks. Several now show classic leader profiles: accelerating earnings, rising fund ownership. Risk: crowded, and priced for it.

[Patrick Morris @patrickmorris]

2/ The "growth without the crowding" trade. Healthcare has lagged on drug-pricing politics, yet forward EPS growth runs ~14% at valuations well below tech. If AI capex momentum stalls, this is the likeliest landing spot for growth capital. Risk: policy headlines can cap the sector for months.

[Patrick Morris @patrickmorris]

1/ Inside tech itself: capital keeps moving from software to AI hardware. Memory makers are getting triple-digit price hikes. AI infra earnings estimates are up 50%+ since late 2024 while the rest of the index gets cut. Risk: the capex funding those earnings comes from the same few buyers.

[Equity investor @equitydd]

Stocks on watchlist with high earnings growth

$MU $AMD $ASML $AMAT $CAT $LRCX $ARM $GEV $SNDK $DELL $CRWD $WDC $GLW $FTNT $DDOG $ASX $ALAB $UMC $HPE $NBIS $CRDO $CRS $ATI $MKSI $SIMO $PLXS $SLAB $BB $NAVN $KLIC $PTRN $TENB $EXTR $ICHR $OUST $PENG $COHU $PDFS $ATEN

[Patrick Morris @patrickmorris]

$DXY Dollar strength isn't one signal — it's a relative price with four possible drivers:

• Rate differentials — Fed hawkish vs. everyone else
• Relative growth — U.S. best house on the block
• Fear — reserve currency bid in a crisis
• Dollar scarcity — global debtors scrambling

The dollar smile: it rallies when the U.S. booms AND when the world panics. Weakens in the calm middle.

Same move, opposite meanings. Dollar up on yields ≠ dollar up on fear. Check what's moving with it — rates, spreads, equities — before you trade the signal.

[Patrick Morris @patrickmorris]

$META reportedly exploring selling excess compute — from frontier model race to GPU landlord.

Bear read: surplus hyperscaler capacity is a reckoning for neoclouds (CRWV, NBIS).

Bull read: it confirms compute demand is big enough that even Meta wants toll-taker economics.

[Lin @Speculator_io]

One of the strongest sectors outside of AI right now is Biotech.

Oncology
$TNGX Tango Therapeutics
$ELVN Enliven Therapeutics
$RVMD Revolution Medicines
$RLAY Relay Therapeutics
$CGON CG Oncology
$PSNL Personalis
$GH Guardant Health
$NEO NeoGenomics
$INCY Incyte

Neurology
$DFTX Definium Therapeutics
$CMPS COMPASS Pathways
$DNLI Denali Therapeutics
$XENE Xenon Pharmaceuticals
$BIlB Biogen
$NBIX Neurocrine Biosciences
$CPRX Catalyst Pharmaceuticals

Immunology
$ORKA Oruka Therapeutics
$DNTH Dianthus Therapeutics
$APGE Apogee Therapeutics
$IMVT Immunovant
$KNSA Kiniksa Pharmaceuticals
$TGTX TG Therapeutics
$PTGX Protagonist Therapeutics

Genomics
$NTLA Intellia Therapeutics
$EDIT Editas Medicine
$BEAM Beam Therapeutics
$CRSP CRISPR Therapeutics
$ARWR Arrowhead Pharmaceuticals
$KRYS Krystal Biotech
$VCEL Vericel

Rare Diseases
$LQDA Liquidia
$MBX MBX Biosciences
$EWTX Edgewise Therapeutics
$TVTX Travere Therapeutics
$TRVI Trevi Therapeutics
$PVLA Palvella Therapeutics
$VRTX Vertex Pharmaceuticals

Drug Discovery
$TWST Twist Bioscience
$ABSI Absci
$RXRX Recursion
$ABCL AbCellera
$NRIX Nurix Therapeutics

Medical Devices & Life Science Tools
$TWST Twist Bioscience
$ABSIR Absci
$BFLY Butterfly Network
$TXG 10x Genomics
$ABCL AbCellera
$BRKR Bruker
$ALMR Alamar Biosciences
$TECH Bio-Techne